Stay updated with breaking news from Interim Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema PatientsFebruary 28, 2022Interim Real-World Data from Phase 4 EMPOWER Study Show Attack Rate Reduction and Improvement in Treatment Satisfaction and Other Patient-Reported Outcome Scores...
President, ECOWAS Commission, Mr. Jean-Claude Kassi Brou and the Director of the French Development Agency (AFD) in Nigeria, Mr. Xavier Muron have signed a grant agreement for a complementary funding
The Central government is examining the recommendation of the Subject Expert Committee (SEC) regarding the grant of market authorization of Covaxin for the age group of 2 to 18 years for restricted use in an emergency situation subject to various conditions, Ministry of Health and Family Welfare (MoHF) told Rajya Sabha on Tuesday.
The Interim Phase II, III clinical trial data of COVAXIN on Healthy Volunteers aged 2 to 18 years submitted by Bharat Biotech was deliberated in the meeting of the Subject Expert Committee (SEC) on August 28 and October 11, informed Ministry of Health and Family Welfare.
The Central government is examining the recommendation to grant market authorization to Covaxin for the age group of 2 to 18 years.